The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Open accessAbstract
Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa-induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non-human primates with MPTP-induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson's disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Ballard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Anderson, V. C., Burchiel, K. J., Hogarth, P., Favre, J., & Hammerstad, J. P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.554 · Cited by 537
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Nyholm, D., Nilsson Remahl, A. I. M., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., Aquilonius, S. M., & Askmark, H. (2005) · Neurology · doi:10.1212/01.wnl.0000149637.70961.4c · Cited by 432
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
Papa, S. M., & Chase, T. N. (1996) · Annals of Neurology · doi:10.1002/ana.410390505 · Cited by 292
Fluctuations of disability in Parkinson's disease – clinical aspects
Marsden, C. D., Parkes, J. D., & Quinn, N. (1981) · Movement Disorders · doi:10.1016/b978-0-407-02295-9.50012-6 · Cited by 284
Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease
Fine, J., Duff, J., Chen, R., Hutchison, W., Lozano, A. M., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006083422304 · Cited by 266
(2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<2::aid-ana2>3.0.co;2-b · Cited by 249
Be´dard, P. J., Paolo, T. D., Falardeau, P., & Boucher, R. (1986) · Brain Research · doi:10.1016/0006-8993(86)90783-3 · Cited by 244
Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G., Liss, C., Reines, S., Irr, J., & Nibbelink, D. (1997) · European Neurology · doi:10.1159/000117399 · Cited by 234
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Péchevis, M., Clarke, C. E., Vieregge, P., Khoshnood, B., Deschaseaux‐Voinet, C., Berdeaux, G., Ziegler, M., & on behalf of the Trial Study Group (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01096.x · Cited by 196
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
Brotchie, J. M. (2005) · Movement Disorders · doi:10.1002/mds.20612 · Cited by 192
Buspirone in Levodopa-Induced Dyskinesias
Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., & Meco, G. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199402000-00008 · Cited by 181
Subcutaneous Apomorphine: An Evidence-Based Review of its Use in Parkinson???s Disease
Deleu, D., Hanssens, Y., & Northway, M. G. (2004) · Drugs & Aging · doi:10.2165/00002512-200421110-00001 · Cited by 177
Di Monte, D. A., McCormack, A., Petzinger, G., Janson, A. M., Quik, M., & Langston, W. J. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<459::aid-mds1006>3.0.co;2-3 · Cited by 165
Cortical motor overactivation in parkinsonian patients with L-dopa- induced peak-dose dyskinesia
Rascol, O. (1998) · Brain · doi:10.1093/brain/121.3.527 · Cited by 164
Present and future drug treatment for Parkinson's disease
Schapira, A. H. V. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.035980 · Cited by 163
Levodopa‐dyskinesia incidence by age of Parkinson's disease onset
Kumar, N., Van Gerpen, J. A., Bower, J. H., & Ahlskog, J. E. (2005) · Movement Disorders · doi:10.1002/mds.20360 · Cited by 162
Slowing Parkinson’s disease progression: Recent dopamine agonist trials
Ahlskog, J. E. (2003) · Neurology · doi:10.1212/01.wnl.0000044047.58984.2f · Cited by 161
van Everdinge, K. J., Visser, G. H. A., Klijn, C. J. M., Kappelle, L. J., & van der Grond, J. (1998) · Annals of Neurology · doi:10.1002/ana.410440206 · Cited by 155
Dopamine agonists and neuroprotection in parkinson's disease
Olanow, C. W., Jenner, P. G., & Brooks, D. J. (1998) · Annals of Neurology · doi:10.1002/ana.410440725 · Cited by 131
Effect of Long-term Therapy on the Pharmacodynamics of Levodopa
Nutt, J. G. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530350037016 · Cited by 127
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
Bibbiani, F., Costantini, L. C., Patel, R., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.013 · Cited by 123
Molecular basis of levodopa-induced dyskinesias.
Calon, F., Grondin, R., Morissette, M., Goulet, M., Blanchet, P. J., Paolo, T. D., & Bédard, P. J. (2000) · PubMed · Cited by 119
Dopamine D2receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
Oliveri, R. L., Annesi, G., Zappia, M., Civitelli, D., Montesanti, R., Branca, D., Nicoletti, G., Spadafora, P., Pasqua, A. A., Cittadella, R., et al. (1999) · Neurology · doi:10.1212/wnl.53.7.1425 · Cited by 112
Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Movement Disorders · doi:10.1002/mds.10343 · Cited by 110
Levodopa-induced dyskinesias are improved by fluoxetine
Durif, F., Vidailhet, M., Bonnet, A. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.10.1855 · Cited by 107
Fox, S. H., Lang, A. E., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.20936 · Cited by 105
da Silva‐Júnior, F. P., Braga‐Neto, P., Monte, F. S., & de Bruin, V. M. S. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.05.008 · Cited by 90
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston, J. W., Quik, M., Petzinger, G. M., Jakowec, M. W., & Monte, D. A. D. (2000) · PubMed · Cited by 89
Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks
Liu, X., Carroll, C., Wang, S., Zajicek, J., & Bain, P. G. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.10.005 · Cited by 89
Striatal glutamatergic mechanisms and extrapyramidal movement disorders
Chase, T. N., Bibbiani, F., & Oh, J. D. (2003) · Neurotoxicity Research · doi:10.1007/bf03033378 · Cited by 78
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications
Sossi, V., de la Fuente‐Fernández, R., Schulzer, M., Adams, J. R., & Stoessl, A. J. (2006) · Brain · doi:10.1093/brain/awl028 · Cited by 78
Katzenschlager, R., Manson, A. J., Evans, A. H., Watt, H., & Lees, A. J. (2004) · PubMed · Cited by 71
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD–WD-PD cascade)
Sharma, J. C., Macnamara, L., Hasoon, M., Vassallo, M., & Ross, I. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.07.002 · Cited by 71
Suppression of dyskinesias in advanced Parkinson's disease
Schuh, L. A., & Bennett, J. P. (1993) · Neurology · doi:10.1212/wnl.43.8.1545 · Cited by 63
Acute pharmacologic blockade of dyskinesias in Parkinson's disease
Blanchet, P. J., Metman, L. V., Mouradian, M. M., et al. (1996) · Movement Disorders · doi:10.1002/mds.870110516 · Cited by 54
Causes of death in remote symptomatic epilepsy
Day, S. M., Wu, Y. W., Strauss, D., Shavelle, R. M., & Reynolds, R. J. (2005) · Neurology · doi:10.1212/01.wnl.0000169018.44950.68 · Cited by 54
Effect of Riluzole on Dyskinesia and Duration of the ON State in Parkinson Disease Patients
Braz, C. A., Borges, V., & Ferraz, H. B. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200401000-00008 · Cited by 50
Levodopa ethylester : A novel rescue therapy for response fluctuations in parkinson's disease
Djaldetti, R., & Melamed, E. (1996) · Annals of Neurology · doi:10.1002/ana.410390321 · Cited by 42
Chase, T. N. (1973) · Archives of Neurology · doi:10.1001/archneur.1973.00490290068008 · Cited by 39
Subjective Experience of Schizotropic Vulnerability in Siblings of Schizophrenics
Maggini, C., & Raballo, A. (2004) · Psychopathology · doi:10.1159/000077016 · Cited by 37
Marı́n, C., Aguilar, E., & Obeso, J. A. (2006) · Movement Disorders · doi:10.1002/mds.20780 · Cited by 30
(2005) · Archives of Neurology · doi:10.1001/archneur.62.3.430 · Cited by 2
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Spontaneous eye blink rate as predictor of dopamine-related cognitive function—A review
Jongkees, B. J., & Colzato, L. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.020 · Cited by 300
St. Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.037 · Cited by 199
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Mera, T. O., Burack, M. A., & Giuffrida, J. P. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-120166 · Cited by 66
“Dyskinesia significantly impacts quality of life through fatigue, weight loss from excessive movements, social isolation [6], and cases of depression [7].”
Metadata
- Authors
- Thanvi, B., Lo, N., & Robinson, T.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-01
- Volume
- 83
- Issue
- 980
- Pages
- 384-388
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2081384093
- Cited by
- 281
- References
- 55
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.